Ulcerative Colitis Clinical Trial
— ODENOfficial title:
Observational Study of Tofacitinib in Ulcerative Colitis in Sweden (ODEN)
This is a prospective observational study using data from an existing, ongoing National Swedish registry (SWIBREG). This study is designed to assess the effectiveness and treatment adherence of tofacitinib on clinical disease activity parameters in patients with ulcerative colitis in Swedish clinical practice. The study will also assess treatment adherence of tofacitinib using the Swedish Prescribed Drug Register.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | August 14, 2026 |
Est. primary completion date | August 14, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: - The assignment of the patient to tofacitinib is not decided in advance by the protocol but falls within clinical practice and the prescription of the medicine is done according to the SmPC and is clearly separated from the decision to include the patient in the study. - The patient must sign the informed consent before enrollment in the study. The informed consent permits extraction of data from SWIBREG at baseline and during the duration of the study. For patients not registered in SWIBREG, they must complete all SWIBREG consents and registration at the time of treatment initiation. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. - Patients, male or female, must be 18 years old or above. - The patient must have active disease as confirmed by fecal calprotectin >250 mg/kg or endoscopic assessment corresponding to a Mayo endoscopic subscore =2 not more than 4 weeks prior onset to the initiation of tofacitinib treatment. This inclusion criteria applies also to patients that have already been enrolled in the study. Exclusion Criteria: - The patient is enrolled in a clinical trial in which the treatment of ulcerative colitis is dictated by a study protocol. If the patient is participating in another ongoing observational study (non-interventional), the patient may be included in this observational study. - Patients that fulfill any of the contraindications according to the latest version of the SmPC. Any SmPC label updates will be communicated to all study sites. - For whatever reason the physician feels the patient unsuitable to participate in the study. |
Country | Name | City | State |
---|---|---|---|
Sweden | Ulf Eriksson | Alingsås | |
Sweden | Medicinkliniken, Södra Älvsborgs Sjukhus Borås, Brämhultsvägen 53 | Borås | |
Sweden | Gävle Hospital | Gävle | |
Sweden | SU/Sahlgrenska, Gastroenterologi & Hepatologi | Göteborg | |
Sweden | Medicinkliniken, Länssjukhuset Ryhov, Sjukhusgatan | Jönköping | |
Sweden | Daniel Molin | Kristianstad | |
Sweden | Shiprock Consulting AB, | Lidingö | |
Sweden | Mag-Tarmmedicinska kliniken, Universitetssjukhuset i Linköping | Linköping | |
Sweden | Region skåne, Skånes Universitetssjukhus | Malmö | |
Sweden | Medicinmottagning 4, Medicinska Kliniken, Universitetssjukhuset Örebro | Örebro | |
Sweden | Capio S:t Görans Sjukhus, S:t Göransplan 1 | Stockholm | |
Sweden | Danderyds Hospital | Stockholm | |
Sweden | Ersta Sjukhus, Medicinkliniken, Fjällgatan 44 | Stockholm | |
Sweden | Karolinska Universitetssjukhuset i Solna, Eugeniavägen 3, B4-09, | Stockholm | |
Sweden | Stockholm Gastro Center | Stockholm | |
Sweden | Medicinkliniken, Umeås Universitetssjukhus | Umeå | |
Sweden | Specialmedicin, Akademiska Sjukhuset, Sjukhusvägen ing 40 | Uppsala | |
Sweden | Medicinmottagningen gastroenterologi, Västmanlands sjukhus | Västerås |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of Participants in Remission as Measured by Partial Mayo Score | Clinical Remission is defined as a partial score of <2 points with 0 points regarding rectal bleeding. | Week 52 | |
Secondary | Proportion of Participants who are taking tofacitinib | Baseline, Weeks 8, 16, 52, 104 | ||
Secondary | Proportion of Participants in Clinical Remission Based on Total Mayo Score | Clinical Remission is defined as a total Mayo score of =2 points with no individual subscore exceeding 1 point, with 0 points regarding rectal bleeding. | Weeks 8, 16, 52, and 104 | |
Secondary | Proportion of Participants in Clinical Response Based on Total Mayo Score | Clinical Response is defined as a total Mayo score decrease of =3 points and a decrease of =30% from baseline, with a decrease of =1 point on the rectal bleeding subscore or an absolute rectal bleeding score of =1 | Weeks 8, 16, 52, and 104 | |
Secondary | Proportion of Participants in Clinical Remission Based on Partial Mayo Score | Clinical Remission is defined as a partial Mayo score <2 points with 0 points regarding rectal bleeding. | Weeks 8, 16, 52 and 104 | |
Secondary | Proportion of Participants in Clinical Response Based on Partial Mayo Score | Clinical Response is defined as a partial Mayo score decrease of =2 points and reduction of at least 25% in partial Mayo (pMayo) score from baseline with an accompanying decrease in rectal bleeding subscore of =1 point or absolute rectal bleeding subscore of =1 point | Weeks 8, 16, 52 and 104 | |
Secondary | Proportion of Participants in Steroid-Free Clinical Remission | Steroid-Free Clinical Remission is defined by a total Mayo Score who did not require any corticosteroid treatment during the period =4 weeks prior to the visit (for all patients and for those treated with corticosteroids at baseline) | Weeks 16, 52, and 104 | |
Secondary | Change from Baseline in Total Mayo Score | Baseline, Weeks 8, 16, 52, and 104 | ||
Secondary | Change From Baseline In Partial Mayo Score | Baseline, Weeks 8, 16, 52 and 104 | ||
Secondary | Change From Baseline In Level of Fecal Calprotectin (f-calprotectin) | Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation. | Baseline, Weeks 8, 16, 52 and 104 | |
Secondary | Proportion of Responders defined by a Fecal Calprotectin (f-calprotectin) Reduction of =50%, =75% or =90% | Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation. | Weeks 8, 16, 52, and 104 | |
Secondary | Change from Baseline of C-Reactive Protein (CRP) | Baseline, Weeks 8, 16, 52, and 104 | ||
Secondary | Proportion of Participants In Sustained Remission (Partial Mayo score) | Week 8 To Weeks 16, 52 and 104 | ||
Secondary | Proportion of Participants In Sustained Remission (Partial Mayo score) | Week 16 To Weeks 52 and 104 | ||
Secondary | Proportion of Participants in Sustained Steroid Free Remission (Partial Mayo Score) (for all patients and for those treated with corticosteroids at baseline) | Weeks 16 through 52 and at Week 104 | ||
Secondary | Proportion of Participants in Endoscopic Remission, Mucosal Healing or Endoscopic Response | Endoscopic remission is defined as a subscore of 0. Mucosal healing is defined as a subscore of 0-1. Endoscopic response is defined as a subscore reduction from baseline of =1. | Week 8, 16, 52 and 104 | |
Secondary | Proportion of Participants in Sustained Endoscopic Remission, Mucosal Healing or Endoscopic Response | Endoscopic remission is defined as a subscore of 0. Mucosal healing is defined as a subscore of 0-1. Endoscopic response is defined as a subscore reduction from baseline of =1. | Week 8 to Week 16, 52 and 104 | |
Secondary | Proportion of Participants in Sustained Endoscopic Remission, Mucosal Healing or Endoscopic Response | Endoscopic remission is defined as a subscore of 0. Mucosal healing is defined as a subscore of 0-1. Endoscopic response is defined as a subscore reduction from baseline of =1. | Week 16 to 52 and at Week 104 | |
Secondary | Proportion of Participants in Sustained Steroid Free Remission (Partial Mayo Score) (For All Participants and for Those Treated With Corticosteroids at Baseline) and Endoscopic Remission, Mucosal Healing or Endoscopic Response | Endoscopic remission is defined as a subscore of 0. Mucosal healing is defined as a subscore of 0-1. Endoscopic response is defined as a subscore reduction from baseline of =1. | Week 16 to 52 and 104 | |
Secondary | Change From Baseline In Inflammatory Bowel Disease Fatigue (IBD-F) Score | Baseline, Weeks 8, 16, 52 and 104 | ||
Secondary | Change From Baseline In EuroQol 5 Dimensions 5 Levels (EQ5D-5L) | Baseline, Weeks 8, 16, 52, and 104 | ||
Secondary | Change From Baseline In Short Health Scale (SHS) | Baseline, Weeks 8, 16, 52 and 104 | ||
Secondary | Proportion of Participants Who Had a Colectomy | Weeks 8, 16, 52, and 104 | ||
Secondary | Comparison of Response and Remission (Partial Mayo Score) Based on the Extent of Ulcerative Colitis According To the Montreal Classification | Weeks 8, 16, 52 and 104 | ||
Secondary | Proportion of Participants In Sustained Remission (Total Mayo score) | Week 16 To Weeks 52 and 104 | ||
Secondary | Proportion of Participants In Sustained Remission (Total Mayo score) | Week 8 To Weeks 16, 52 and 104 | ||
Secondary | Proportion of Participants in Sustained Steroid Free Remission (Total Mayo Score) (For All Participants and for Those Treated With Corticosteroids at Baseline) and Endoscopic Remission, Mucosal Healing or Endoscopic Response | Endoscopic remission is defined as a subscore of 0. Mucosal healing is defined as a subscore of 0-1. Endoscopic response is defined as a subscore reduction from baseline of =1. | Week 16 to 52 and 104 | |
Secondary | Proportion of Participants in Sustained Steroid Free Remission (Total Mayo Score) (for all patients and for those treated with corticosteroids at baseline) | Weeks 16 through 52 and at Week 104 | ||
Secondary | Comparison of Response and Remission (Total Mayo Score) Based on the Extent of Ulcerative Colitis According To the Montreal Classification | Weeks 8, 16, 52 and 104 | ||
Secondary | Proportion of Participants in Steroid-Free Clinical Remission | Steroid-Free Clinical Remission is defined by a partial Mayo Score who did not require any corticosteroid treatment during the period =4 weeks prior to the visit (for all patients and for those treated with corticosteroids at baseline) | Weeks 16, 52, and 104 | |
Secondary | Proportion of participants reaching f-calprotectin below 250 mg/kg of those that had f-calprotectin above 250 mg/kg at baseline | Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation. | Baseline, week 8, 16, 52 and 104 | |
Secondary | Portion of participants with dose change of tofacitinib | Week 8, 16, 52 and 104 | ||
Secondary | Portion of participants with a termination of tofacitinib | Week 8, 16, 52 and 104 | ||
Secondary | Portion of participants with dose and dose changes of tofacitinib and corticosteroids | Week 8, 16, 52 and 104 | ||
Secondary | Proportion of particpants with changes in rectal bleeding and stool frequency | Proportion of patients with improvement in rectal bleeding and stool frequency with a change in baseline sub score 1 | Baseline, Week 2 | |
Secondary | Proportion of participants with changes in EQ5D and SHS | Baseline, Week 2 | ||
Secondary | Proportion of particpants with rectal bleeding and stool frequency sub score indicative of mild disease | Baseline, Week 2 | ||
Secondary | Proportion of participants with stool frequency and rectal bleeding subscore of 0 | Baseline, Week 2 | ||
Secondary | Proportion of participants with mild abdominal pain | Baseline, Week 2 | ||
Secondary | Proportion of participants with no abdominal pain | Baseline, Week 2 | ||
Secondary | Proportion of participants with no bowel urgency | Baseline, Week 2 | ||
Secondary | Proportion of participants with reduction of = 1 point from baseline rectal bleeding and stool frequency sub score | Baseline, Week 2 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |